/DRIO
DRIO Stock - DarioHealth Corp.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$11.54-10.12%
$1.30 (-10.12%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.21
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.77
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+38.6%upside
Target: $15.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DRIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.42 – $11.66
TARGET (TP)$16.00
STOP LOSS$10.62
RISK/REWARD1:4.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.08
52W High$31.00
52W Low$5.93
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $27.04M | $20.35M | $27.66M | $20.51M | $7.58M |
| Gross Profit | $13.27M | $5.98M | $9.65M | $8.07M | $2.51M |
| Gross Margin | 49.1% | 29.4% | 34.9% | 39.3% | 33.2% |
| Operating Income | $-57,744,000 | $-56,189,000 | $-56,810,000 | $-76,494,000 | $-29,903,000 |
| Net Income | $-42,747,000 | $-59,427,000 | $-62,193,000 | $-76,761,000 | $-29,445,000 |
| Net Margin | -158.1% | -292.0% | -224.9% | -374.2% | -388.7% |
| EPS | $0.61 | $-1.93 | $-2.63 | $-4.63 | $-5.55 |
Company Overview
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
50%
Hold / Neutral
1
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
1 Bullish1 Neutral/Bearish
Price Targets
$5
Average Target
↓ 57.8% Downside
Now
$1
Low
$5
Average
$9
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 29th 2025 | TD Cowen | Downgrade | Hold | $1← $2 |
| May 13th 2022 | Alliance Global Partners | Upgrade | Buy | $8.75 |
Earnings History & Surprises
DRIOBeat Rate
78%
Last 18 quarters
Avg Surprise
+33.1%
EPS vs Estimate
Beats / Misses
14/4
Last 12 quarters
Latest EPS
$-1.85
Q4 2025
EPS Surprise History
Q1 24
+24.1%
$-8.20vs$-10.80
Q2 24
+66.1%
$-4.00vs$-11.80
Q3 24
+120.7%
$1.20vs$-5.80
Q4 24
+27.8%
$-2.60vs$-3.60
Q1 25
+106.3%
$0.20vs$-3.20
Q2 25
+14.3%
$-1.20vs$-1.40
Q3 25
-9.1%
$-2.40vs$-2.20
Q4 25
+29.7%
$-1.85vs$-2.63
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 9, 2026 | $-1.56 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-2.63 | $-1.85 | +29.7% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-2.20 | $-2.40 | -9.1% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-1.40 | $-1.20 | +14.3% | ✓ BEAT |
Q1 2025 | Mar 10, 2025 | $-3.20 | $0.20 | +106.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-3.60 | $-2.60 | +27.8% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-5.80 | $1.20 | +120.7% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-11.80 | $-4.00 | +66.1% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-10.80 | $-8.20 | +24.1% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-10.00 | $-9.80 | +2.0% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-10.40 | $-11.60 | -11.5% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-9.20 | $9.00 | +197.8% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-12.00 | $-10.20 | +15.0% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-16.60 | $-12.80 | +22.9% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-15.40 | $-14.80 | +3.9% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-19.60 | $-14.80 | +24.5% | ✓ BEAT |
Q1 2022 | Mar 22, 2022 | $-22.60 | $-21.80 | +3.5% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-19.00 | $-23.60 | -24.2% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-16.80 | $-19.80 | -17.9% | ✗ MISS |
Latest News
DarioHealth Publishes Peer-Reviewed Study Titled "The Impact of Digital Intervention Messages Targeting Users With High Blood Pressure Events: Retrospective Real-World Study," In JMIR Cardio.
📈 PositiveBenzinga•Dec 4, 2025, 01:10 PM
DarioHealth Announces The Publication Of A New Peer-Reviewed Study In The Journal Of Medical Internet Research Showing Digital Diabetes Platform Cuts Hospitalizations 23% And Healthcare Costs 26% Vs. Usual Care
📈 PositiveBenzinga•Nov 24, 2025, 01:12 PM
DarioHealth Q3 Adj. EPS $(1.91) Beats $(4.90) Estimate, Sales $5.007M Miss $5.665M Estimate
➖ NeutralBenzinga•Nov 13, 2025, 11:15 AM
DarioHealth Highlights Presentation At ISPOR Europe 2025 On Medical Cost Reduction Using Its Digital Health Platform
📈 PositiveBenzinga•Nov 12, 2025, 01:39 PM
DarioHealth Adds Six Employer Clients, Launches Value-Based Pricing Framework Tied To Engagement And Clinical Progress; Platform Delivers 5X ROI And $5K Annual Savings per User
📈 PositiveBenzinga•Oct 13, 2025, 12:35 PM
DarioHealth And OneStep Collaborated To Integrate OneStep's Clinical-grade Fall Risk Assessment And Prevention Capabilities Within DarioHealth's Digital Health Solutions Ecosystem
📈 PositiveBenzinga•Oct 6, 2025, 11:40 AM
DarioHealth shares are trading higher after the company announced a strategic review following multiple unsolicited expressions of interest.
📈 PositiveBenzinga•Sep 25, 2025, 04:52 PM
DarioHealth Launches Strategic Review After Interest From Buyers, Weighs Sale Or Merger Options
📈 PositiveBenzinga•Sep 25, 2025, 10:04 AM
DarioHealth shares are trading higher after the company announced a private placement of 2.7 million shares at $6.45 per share for expected gross proceeds of about $17.5 million.
📈 PositiveBenzinga•Sep 22, 2025, 07:02 PM
DarioHealth Announced A Private Placement Of 2.7M Shares At $6.45 Per Share For Expected Gross Proceeds Of Approximately $17.5M
➖ NeutralBenzinga•Sep 22, 2025, 11:13 AM
DarioHealth Lands 5 Major Employer Contracts For Cardiometabolic Health Platform, Eyes 40 New Deals By Year-End
📈 PositiveBenzinga•Sep 2, 2025, 11:32 AM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Aug 28, 2025, 12:55 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Aug 27, 2025, 11:50 PM
DarioHealth Announces 20-For-1 Reverse Stock Split Effective August 28, Reducing Outstanding Shares To 2.4M
📉 NegativeBenzinga•Aug 25, 2025, 12:10 PM
Frequently Asked Questions about DRIO
What is DRIO's current stock price?
DarioHealth Corp. (DRIO) is currently trading at $11.54 per share. The stock has moved -10.12% today.
What is the analyst price target for DRIO?
The average analyst price target for DRIO is $16.00, based on 1 analyst.
What sector is DarioHealth Corp. in?
DarioHealth Corp. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is DRIO's market cap?
DarioHealth Corp. has a market capitalization of $0.08 billion, making it a small-cap company.
Does DRIO pay dividends?
No, DarioHealth Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABSI
Absci Corporation
$3.38
Mkt Cap: $0.5B
AVNS
Avanos Medical, Inc.
$11.67
Mkt Cap: $0.5B
FLGT
Fulgent Genetics, Inc.
$27.61
Mkt Cap: $0.8B
INNV
InnovAge Holding Corp.
$6.00
Mkt Cap: $0.8B
MYGN
Myriad Genetics, Inc.
$6.55
Mkt Cap: $0.6B
NNNN
Anbio Biotechnology Class A Ordinary Shares
$32.35
Mkt Cap: $1.4B
OFIX
Orthofix Medical Inc.
$15.46
Mkt Cap: $0.6B
PACB
Pacific Biosciences of California, Inc.
$1.84
Mkt Cap: $0.6B
RGNX
REGENXBIO Inc.
$14.59
Mkt Cap: $0.7B
VSTM
Verastem, Inc.
$7.76
Mkt Cap: $0.5B
Explore stocks similar to DRIO for comparison